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Abstract
Introduction: Breast cancer heterogeneity occurs as a consequence of the dysregulation of numerous oncogenic
pathways as well as many non-genetic factors, including tumor microenvironmental stresses such as hypoxia, lactic
acidosis, and glucose deprivation. Although the importance of these non-genetic factors is well recognized, it is
not clear how to integrate these factors within the genetic framework of cancer as the next logical step in
understanding tumor heterogeneity.
Methods: We report here the development of a series of gene expression signatures to measure the influences of
microenvironmental stresses. The pathway activities of hypoxia, lactic acidosis, acidosis and glucose deprivation
were investigated in a collection of 1,143 breast tumors, which have been separated into 17 breast tumor
subgroups defined by their distinct patterns of oncogenic pathways. A validation dataset comprised of 547 breast
tumors was also used to confirm the major findings, and representative breast cancer cell lines were utilized to
validate in silico results and mechanistic studies.
Results: Through the integrative pathway analysis of microenvironmental stresses and oncogenic events in
breast tumors, we identified many known and novel correlations between these two sources of tumor
heterogeneity. Focusing on differences between two human epidermal growth factor receptor 2 (HER2)-related
subgroups, previously identified based on patterns of oncogenic pathway activity, we determined that these
subgroups differ with regards to tumor microenvironmental signatures, including hypoxia. We further
demonstrate that each of these subgroups have features consistent with basal and luminal breast tumors
including patterns of oncogenic signaling pathways, expression of subtype specific genes, and cellular
mechanisms that regulate the hypoxia response. Importantly, we also demonstrate that the correlated pattern of
hypoxia-related gene expression and basal-associated gene expression are consistent across HER2-related tumors
whether we analyze the tumors as a function of our pathway-based classification scheme, using the intrinsic
gene list (ERBB2+), or based on HER2 IHC status. Our results demonstrate a cell lineage-specific phenomenon in
which basal-like tumors, HER2-related tumors with high hypoxia, as well as normal basal epithelial cells express
increased mRNA levels of HIF-1a compared to luminal types and silencing of HIF-1a results in decreased
expression of hypoxia-induced genes.
Conclusions: This study demonstrates differences in microenvironmental conditions in HER2-related subgroups
defined by distinct oncogenic pathway activities, and provides a mechanistic explanation for differences in the
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any medium, provided the original work is properly cited.observed hypoxia response between these subgroups. Collectively, these data demonstrate the potential of a
pathway-based classification strategy as a framework to integrate genetic and non-genetic factors to investigate
the basis of tumor heterogeneity.
Introduction
Breast cancer is a collection of distinct diseases charac-
terized by differences in oncogenic mechanisms and
clinical characteristics including prognosis and response
to therapeutic regimens. Clinically, tumors are classified
on the basis of tumor size, visual characteristics, and a
limited number of histochemical markers including
estrogen receptor, progesterone receptor and HER2
receptor status. While the strongest and most consistent
division in breast cancer is between the basal and lumi-
nal types and systematic differences strongly suggest a
different cell of origin for these two dominant categories
[1-5] additional molecular or mechanistic heterogeneity
can be identified within classes.
Amplification of HER2 (ERBB2)o c c u r si na p p r o x i -
mately 15 to 25% of human breast tumors and defines a
clinically unique subgroup of breast tumors [6]. Despite
the introduction of Herceptin (trastuzumab), a monoclo-
nal antibody that therapeutically targets HER2, the prog-
nosis for these patients remains poor since a substantial
number of patients either fail to respond to this therapy
or develop resistance over time [7-10]. Therefore, it is
clear that additional heterogeneity exists within this class
of tumors. A number of recent studies have demon-
strated the genomic complexity of HER2+ tumor hetero-
geneity, reporting that these tumors have varied and
complex patterns of copy number alterations, global gene
expression, and DNA methylation [11,12]. Moreover,
molecular subtypes based on analysis of gene expression
patterns [13] as well as more complex analyses of pat-
terns of oncogenic and tumor suppressor pathway activ-
ity [14] have identified further subtypes that provide
additional insight into the molecular and clinical hetero-
geneity of HER2+ tumors beyond the original ERBB2+
classification [1-5]. These studies also suggest that
further investigation of the basis of HER2+ tumor hetero-
geneity, including the interaction of genetic and non-
genetic factors, is necessary to fully elucidate the molecu-
lar mechanisms driving HER2-mediated oncogenesis.
Inherited germline mutations as well as acquired
somatic mutations, unique to each individual patient,
provide a source of variation at the genetic level. How-
ever, additional variation in the environmental condi-
tions further influence tumor phenotypes and select for
tumors adapted for growth within these microenviron-
ments. The most visible of these environmental factors
relate to common changes in the physical and chemical
alterations of cancers, including reduced oxygen tension
(hypoxia), high lactate, extracellular acidosis (lactic
acidosis), and glucose depletion [15-18]. These changes
may result from poor tissue perfusion, abnormal tumor
vasculature, and/or genetic dysregulation of metabolism
in the cancer cell.
Hypoxia (or low pO2) is recognized as a risk factor for
poor clinical outcomes and increased metastasis, partly
due to the gene expression response to hypoxia [18].
The cellular response to hypoxia is triggered by the sta-
bilization of hypoxia regulators, HIF-1a or EPAS1 (HIF-
2a) proteins, under limited oxygen. However, the HIF
protein stabilization and hypoxia response are not lim-
ited to low pO2 and may also result from a wide range
of genetic alterations and signaling malfunctions. These
conditions represent “pseudo-hypoxia” and include the
loss of VHL [19], TP53 [20], or PTEN [21] or activation
of PI3-kinase/Akt [22] and HER2 [23] pathways. In
addition, the HIF genes can also be expressed at differ-
ent levels among different cells and contribute to the
varying degrees of hypoxia response [24,25]. Hypoxia
also favors glycolysis and leads to lactic acidosis with
the accumulation of lactate and acidity in solid tumors.
Avid glucose uptake and glycolysis can lead to glucose
deprivation, another stress found in solid tumors
[26,27]. Glucose deprivation triggers activation of
AMPK and LKB-1, which in turn activates TSC1/TSC2
and inhibits the central energy sensor mTOR [28]. In
addition, long term exposure to glucose deprivation has
been shown to contribute to KRAS mutation in human
cancers [29].
Given the importance of these microenvironmental
stresses, many methods have been developed to measure
their occurrence in solid tumors. These methods include
direct measurements of oxygen tension (EF5, Eppendorf
polarographic probe), acidity (pH probes), and lactate/
glucose levels (bioluminescence technique) [30-33].
These approaches allow us to obtain a calibrated map of
the respective metabolites’ distributions within the
tumor tissues that indicates relative abundance and spa-
tial distribution. The level of each of these stresses in
viable tumor areas shows large variations between
tumors and can be related to tumor behavior and differ-
ent clinical risks [30,34-38]. Therefore, an ability to
assess these physiological parameters prior to treatment
has the potential to aid in the development of novel
therapeutic strategies for individual patients.
Drawbacks to these in vivo tumor measurements are
that they are frequently invasive, technically challenging,
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laboratory setting; they are not amenable to routine and
optimal clinical care. We have been working towards
developing a conceptual framework to evaluate and
incorporate the influences of these stresses to better
understand the basis of tumor heterogeneity. The influ-
ence of tumor environment can be manifested by the
expression of “endogenous” response genes; for example,
tissue hypoxia can be inferred by elevated levels of CA9
[39]. When the cellular response genes are captured by
microarrays in the form of “gene signatures”,t h e s ein
vitro derived gene expression signatures are capable of
quantitatively assessing and classifying tumors based on
their environmental profile analogous to oncogenic
pathway activation and other phenotypes [24,40-45].
We recently reported the development of a tumor
classification strategy based on patterns of oncogene
and tumor suppressor activity as measured by gene
expression signatures of each oncogenic pathway [14].
This study identified 17 breast tumor subgroups that are
associated with the intrinsic subtypes of breast cancers
and have shown an ability to further delineate potential
mechanisms of disease by identifying novel patterns of
oncogenic pathway activity and copy number variation
between subgroups [1,46]. In the current study, we
apply a similar framework towards understanding the
nature of environmental and metabolic stresses in the
context of defined lineage and oncogene specific tumor
characteristics. Our findings indicate that a strong
hypoxic response is the most characteristic of basal type
tumors, which extends to a subset of HER2 related can-
cers that express characteristics consistent with deriva-
tion from the basal lineage. These differences in the
hypoxia responses are likely due to the cell-type specific
expression levels of HIF mRNAs which are associated
with mammary differentiation programs.
Materials and methods
Gene expression signatures and tumor samples
The methods and a description of the training data used
to develop the oncogenic pathway gene expression signa-
tures have been published [14] and a detailed description
of the methods, including the training data, for the devel-
opment of the microenvironment signatures as well as
for signatures to measure basal-luminal and subgroup 7/
10 characteristics are provided in the Additional file 1,
Supplemental methods section. Signature parameters,
genes, and regression weights for the microenvironment
signatures are reported in Additional file 2 Table S1.
Briefly, a signature represents a group of genes that col-
lectively demonstrate a consistent pattern of expression
in relation to a given phenotype. Each signature is
derived from the first principal component or the factor
corresponding to the largest singular value as determined
by singular value decomposition. A binary probability
regression model is then estimated using Bayesian meth-
ods based on the vectors representing the two phenotypic
states of the training data. The gene selection, identifica-
tion, and regression model is based solely on the training
data and maintains statistical independence from the
validation dataset. This enables evaluation of predictive
probabilities of each of the two phenotypic states in the
training data for each sample in the validation datasets.
Two previously described meta-datasets containing
expression data from 1,143 and 547 human breast tumor
samples respectively, were collected from 10 and 2 inde-
pendent datasets for which Affymetrix HG-U133 CEL
files were publicly available [14]. A summary of publicly
available samples utilized in the study is provided in
Additional file 3, Table S2. Samples were first RMA or
MAS5 normalized using Affymetrix Expression Console
ver1.0. MAS5 data were log2 transformed and both RMA
and log2MAS5 datasets were filtered to include only
those probes on the Affymetrix (Santa Clara, CA, USA)
HG-U133A array. Samples were then normalized by
Bayesian Factor Regression Analysis (BFRM) to remove
technical variation as previously reported [14]. All studies
using human data were performed in compliance with
the Helsinki Declaration.
Cell culture
AU565 and HCC202 cells were maintained in RPMI
with 15% FBS and 1% penicillin/streptomycin while
MCF7, BT474, CAMA1, BT20, MDAMB231, and
MDAMB157 were cultured in DMEM with 10% FBS
and 1% penicillin/streptomycin. Primary luminal and
basal cells are obtained from human breast organoids
and isolated as described [47]. For hypoxia, cells were
cultured under 1% O2 for 4 or 24 hours.
RNA interference and overexpression
The cells were plated in six-well plates at a density of
3×1 0
5 cells per well. For RNAi, cells were transfected
with control non-targeting or siRNA against HIF-1a or
HIF-2a with lipofectamine (Invitrogen, Carlsbad, CA,
USA). RNA was extracted 48 hours after transfection
and the levels of indicated transcripts were examined by
real-time RT-PCR.
Real-time RT-PCR
Total RNAs from cells, including cancer cell lines and
primary breast cells, under normal culture condition or
48 h of hypoxia (1% O2) were isolated using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and then
reverse-transcribed to cDNAs with SuperScript II reverse
transcription kit (Invitrogen, Carlsbad, CA, USA) and
used for real-time PCR with Power SYBRGreen PCR Mix
(Applied Biosystem, Foster City, CA, USA) and primers
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GTTTCCTCACACGCA), EPAS1 (CCATGTCTCCA
CCTTCAGA, GCTTCAGCTTCAGCTTGTTG), ACTB
(b-actin) (CTCTTCCAGCCTTCCTTCCT, AGCACT
GTGTTGGCGTACAG), CA9 (TCCTCAAGAACCCCA-
GAATAA, CCTCCATAGCGCCAATGACT), GLUT1
(AACTCTTCAGCCAGGGTCCAC, CACAGTGAA-
GATGATGAAGAC), VEGFA (TGCTCTACCTCCAC-
CATGCCAA, TGATGATTCTGCCCTCCTCCTTC).
The relative levels of each gene from real-time PCR were
normalized with the level of b-actin.
Analysis of gene expression levels
To compare relative levels of expression for individual
genes or the average of several related genes, RMA nor-
malized Affymetrix U133A expression data from the pri-
mary or the validation datasets were compared. The
Affymetrix probes used for each gene or condition are
reported in the Supplemental methods. For the analysis
of the average basal-like or hypoxia-related gene expres-
sion, probes associated with each condition, reported in
the Supplemental methods, were averaged across each
sample. An unpaired t-test or Mann-Whitney U-test, as
reported in the text, was used to compare between
groups and a linear regression was used to compare
expression values on a continuous variable scale.
Results
Analysis of co-regulation of oncogenic signaling and
microenvironment pathways in breast cancer
To investigate the influence of genetic and non-genetic
factors in human breast cancer, we first constructed
gene expression signatures to define the influences of a
series of microenvironmental stresses and then analyzed
them in the context of previously defined oncogenic
pathways. We developed a series of novel gene expres-
sion signatures capable of quantitatively assessing the
influence of hypoxia, lactic acidosis, acidosis, and glu-
cose depletion (Glu(-)) using previously published gene
expression studies of breast cells [42,44,48] (Additional
file 4 Figure S1 and Additional file 3, Table S1). The
pathway activities of these stress signatures were inte-
grated with a series of 18 previously reported oncogenic
pathway signatures using a Bayesian binary regression
strategy to quantitatively assess the stress pathway activ-
ities in a collection of 1,143 human breast tumors that
were collected from 10 independent datasets and nor-
malized by Bayesian Factor Regression Modeling
(BFRM) to remove technical variation [14]. The pre-
dicted hypoxia and lactic acidosis pathway activities
were further validated by their respective significant cor-
relations with the average expression levels of previously
defined hypoxia-inducible genes [24] and the expression
of TXNIP, which is induced by lactic acidosis and is the
putative marker of the lactic acidosis response [44]
(Additional file 4, Figure S1). Concurrently, the pre-
dicted probabilities of 18 oncogenic signaling pathways
were determined in this dataset [14] (Figure 1) to enable
the integrative analysis.
Two-way hierarchical clustering (Figure 1A) and a Pear-
son correlation (Figure 1B) was calculated to define the
statistical correlation between co-activated pathways
These analyses identify three separate clusters of path-
ways with a clear clustering among the hypoxia, Glu(-)
and acidosis pathways together with the EGFR, TGFb,
HER2, TNFa and STAT3 pathways (Figure 1A). A sig-
nificant relationship was also identified between the ER,
PR, and p53 pathways which were found to be grouped
with lactic acidosis pathway activity in a second cluster
(Figure 1). Our previous study on the patterns of onco-
genic pathway activity in human breast tumors [14]
demonstrated clear correlations between the interferon
pathways as well as between MYC and RAS, which are
consistent with the findings of many other studies
[49-51]. As illustrated in Figure 1A, these correlations
persist with the inclusion of environmental conditions.
Moreover, we are able to confirm the previously identi-
fied positive and negative relationships between lactic
acidosis with p53 and PI3K/AKT pathways, respectively
[42]. Finally, the positive correlation and clustering of
the hypoxia pathway with EGFR, TGFb and STAT3 was
consistent with their reported reciprocal positive regula-
tion [52,53]. The re-discovery of these connections
among different pathways in human tumors provides a
measure of validation for the expression signatures and
the predictive approach to integrate genetic and non-
genetic sources of tumor phenotypes.
Analysis of microenvironment conditions in pathway-
defined subgroups of breast cancer identifies differences
between HER2 related subgroups
We recently reported the identification of 17 breast can-
cer subgroups based on patterns of 18 different onco-
gene and tumor suppressor pathway activities [14].
These subgroups, while not simply a refinement of the
molecular subtypes defined by the intrinsic gene list
(that is, basal, luminal A, luminal B, ERBB2+, normal-
like), have been shown to be significantly associated
with these intrinsic subtypes to further delineate biologi-
cal and clinical heterogeneity within these groups.
Therefore, we next investigated microenvironmental
stress pathway activities in the context of these 17 sub-
groups (Additional file 4, Figure S2). Interestingly, in
subgroups 7 and 10, which are characterized by high
levels of HER2 pathway activity (Additional file 4, Figure
S2) and have been shown to be enriched for ERBB2+
tumors [14], the pathway activities of hypoxia/EGFR/
TNFa/TGFb/STAT3 showed consistently higher levels
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2B). As illustrated in Figure 2Aand quantitatively
assessed in Figure 2B, clear differences in patterns of
predicted microenvironmental pathway activities, specifi-
cally hypoxia response, glucose depletion, and acidosis,
as well as a number of hypoxia-associated oncogenic
signaling pathways, including EGFR/TNFa/TGFb/
STAT3, are characteristically different between sub-
groups 7 and 10. To quantitatively assess these differ-
ences, an unpaired t-test was used to compare patterns
of predicted pathway activity in each subgroup (Figure
2B and Additional file 4, Figure S3). We found that sub-
group 7 has significantly (P <0.0001, unpaired t-test)
higher levels of predicted hypoxia response and many
other pathways that were shown to be clustered with
hypoxia, including EGFR, TGFb,T N F a, STAT3, Glu(-)
and acidosis (Figure 2A and Additional file 4 Figure S3).
In contrast, tumors assigned to subgroup 10 had signifi-
cantly higher levels of ER, PR, IFNa, IFNgand SRC path-
way activity (Additional file 4, Figure S3). In order to
validate the differences in patterns of microenvironmen-
tal pathway activity, a validation dataset comprised of
547 independent breast tumor samples was assessed for
patterns of oncogenic pathway activity and assigned to
subgroups [14]. Patterns of microenvironmental pathway
activity were then assessed (Figure 2C) and examined
quantitatively (Figure 2D) demonstrating patterns of
microenvironmental pathway activity in subgroups 7
and 10 consistent with the discovery dataset of 1,143
samples. Specifically, this independent, validation dataset
also demonstrates a significant difference (unpaired t-
test) in patterns of hypoxia response, glucose depletion,
and acidosis (Figure 2D).
Subgroup 7 tumors exhibit a strong hypoxia response
Since tumors in subgroup 7 were characterized by a
higher level of hypoxia response (Figure 2 and Additional
file 4, Figure S3) when compared to subgroup 10 tumors
in both a primary and validation dataset, we next exam-
ined whether these tumors showed differences in expres-
sion of known hypoxia-induced genes. As shown in
Figure 3A and 3B (and in higher resolution in Additional
file 4, Figures S4A and S4B), subgroup 7 tumors demon-
strated higher expression levels of a panel of previously-
defined common hypoxia-induced genes [24] (list of 89
Affymetrix probes provided in Supplemental methods) in
both the primary (Figure 3A) and validation (Figure 3B)
datasets. Consistent with these observations, significantly
higher mRNA levels of many hypoxia-induced genes
including VEGFA (P = 0.0004, Mann-Whitney U-test),
EGLN3 (P <0.0001), GLUT1 (P = 0.0121), and DEC1 (P
<0.0001) were observed in subgro up 7 tumors (Addi-
tional file 4, Figure S5). Collectively these data suggest
that tumors in subgroups 7 and 10, while both sharing
high HER2 pathway activity, differ not only in patterns of
oncogenic pathway signaling but are also characterized
by differences in the degrees of hypoxia response.
In order to understand the basis for the exaggerated
hypoxia response observed in subgroup 7 tumors, we
next analyzed gene expression levels of hypoxia regula-
tors in these tumors. It was determined that subgroup 7
tumors demonstrated a greater than two-fold higher
level of mRNA expression (P <0.0001, Mann-Whitney
U-test) for both HIF1A (HIF-1a)( F i g u r e s3 C ,D )a n d
EPAS1 (HIF-2a) (Figures 3F, G) as compared to sub-
group 10 tumors in both the primary (Figures 3C, F)
and validation datasets (Figures 3D, G). While HIF-1a
and HIF-2a are usually regulated at the protein level via
oxygen-dependent degradation, several studies have
reported a similar mRNA induction associated with a
stronger hypoxia response [24,25]. To further validate
the hypoxia response in subgroup 7 tumors, a number
of additional known hypoxia regulators were identified
from BioCarta, and it was determined that subgroup 7
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Figure 1 Patterns of oncogene, tumor suppressor and microenvironment pathway activity in human breast cancer.( A)H e a t m a p
depicting the two-way hierarchical clustering of patterns of indicated microenvironment stresses (labeled in red) together with oncogenic
pathway activities (labeled in black) in a collection of 1,143 human breast tumors. Red and blue indicates a high and low probability of pathway
activity, respectively. (B) Pearson Correlation Coefficient (r) values between the activities of the 22 indicated pathways.
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of ARNT (P = 0.0078), EP300 (P = 0.009), JUN (P
<0.0001), and LDHA (P = 0.0092) (Additional file 4, Fig-
ure S6). Because several studies have also linked the
level of HER2 amplification to the hypoxia pathway
[23,54], we compared the mRNA levels of HER2 among
these two HER2 related subgroups and found no signifi-
cant difference in either the primary or validation data-
sets (Additional file 4, Figure S6).
As we noted previously [14], a clear advantage of uti-
lizing the pathway-based classification scheme is an abil-
ity to assign new samples including cancer cell lines to
corresponding subgroups based on the similarity of
pathway composition. Therefore, we took advantage of
this ability to identify in vitro cell culture model systems
to test differences between subgroups 7 and 10. Using a
previously analyzed dataset of 50 breast cancer cell lines
[14], we identified two HER2+ breast cancer cell lines
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Figure 2 HER2 related subgroup 7 is characterized by increased pathway activities of hypoxia and other stresses.( A)H e a t m a p
identifying patterns of oncogenic and micro-environmental pathways activity in the HER2 related tumor subgroups 7 (n = 53) and 10 (n = 59)
in the primary dataset of 1,143 tumors; red indicates high predicted pathway activity, blue, low pathway activity. (B) Quantitative assessment of
predicted probabilities of microenvironmental conditions in primary dataset demonstrating significantly higher hypoxia (P <0.0001), glucose
deprivation (P <0.0001), and acidosis (P <0.0001) but no difference in lactic acidosis levels (P = 0.5140). (C) Heatmap identifying patterns of
oncogenic and micro-environmental pathways activity in the HER2 related tumor subgroups 7 (n = 37) and 10 (n = 47) in the validation dataset
of 547 tumors; red indicates high predicted pathway activity, blue, low pathway activity. (D) Quantitative assessment of predicted probabilities of
microenvironmental conditions in primary dataset demonstrating significantly higher hypoxia (P = 0.0149), glucose deprivation (P <0.0001), and
acidosis (P = 0.0008) but no difference in lactic acidosis levels (P = 0.0697).
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(HCC202), each with a probability of subgroup member-
ship greater than 0.90. Consistent with tumor data, we
determined that the subgroup 7 cell line (AU565) has
significantly higher mRNA levels of HIF1A (HIF-1a)
(Figure 3E) and EPAS1 (HIF-2a) (Figure 3H) when com-
pared to the subgroup 10 cell line HCC202. Moreover,
when both cell lines were grown under hypoxic condi-
tions, AU565 cells exhibited a much stronger hypoxia
response as measured by higher mRNA levels of several
hypoxia-inducible genes (Additional file 4, Figure S7).
This is consistent with an enhanced hypoxia response
and higher hypoxia-inducible factor levels in the sub-
group 7 breast tumors.
HER2 related subtypes exhibit basal and luminal type cell
features
It has been reported that basal-like breast tumors have a
significantly more robust hypoxia response compared to
luminal-type breast cancers [55], similar to the differen-
tial hypoxia response between the two identified HER2
related subgroups. In addition, basal breast tumors are
characterized by low ER and PR expression as well as
high levels of EGFR [1,46], elevated expression of AKT3
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Figure 3 Subgroup 7 tumors are characterized by increased levels of hypoxia-related gene expression. Subgroup 7 tumors express
higher levels of hypoxia-induced genes as compared to subgroup 10 tumors in the (A) primary and the (B) validation datasets. Subgroup 7
tumors express significantly higher levels of HIF-1a mRNA in the (C) primary dataset (P <0.0001) and (D) the validation dataset (P = 0.0016) when
compared to subgroup 10 tumors as examined by microarray analysis. (E) Subgroup 7 representative cell line AU565 (P <0.0001) demonstrated
higher levels of HIF-1a expression as compared subgroup 10 cell line, HCC202 when examined by RT-PCR under normal (21% O2) and hypoxic
(1% O2) conditions. Similarly, significantly higher expression of EPAS1 (HIF-2a) was noted in the subgroup 7 in (F) the primary dataset (P
<0.0001) and (G) the validation dataset (P <0.0001) when compared to subgroup 10 tumors by microarray analysis. AU565 (P <0.0001)
demonstrated higher levels of EPAS1 (HIF2a) expression as compared subgroup 10 cell line, HCC202, when examined by RT-PCR under normal
(21% O2) and hypoxic (1% O2) conditions.
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sion [1]; features that are also consistent with each of
the HER2 related subgroups investigated in the current
study. Recent studies have also suggested that HER2
related tumors may be derived from late luminal progeni-
tor cells, an intermediate differentiation stage between
luminal progenitor cells from which basal-like tumors
arise and differentiated luminal cells from which luminal
A and B tumors arise [58,59]. Therefore, we next investi-
gated whether the two HER2 related subgroups might
have additional characteristics consistent with basal and
luminal tumors in addition to being HER2+.
We first measured differences in expression patterns
of pathways and genes known to be differentially
expressed in basal and luminal breast tumors. As shown
in Figure 2 (and Additional file 4, Figure S3), tumors in
subgroup 7 exhibit significantly higher hypoxia and
EGFR pathway activity and lower levels of ER and PR
pathway activity [55,60] when compared to tumors in
subgroup 10, suggesting that tumors in subgroup 7 and
10 tumors, in addition to being HER2+, have basal-like
and luminal-like patterns of pathway activities, respec-
tively. Next, we compared the expression of several
b a s a la n dl u m i n a ls p e c i f i cg e n e si nt h et w oH E R 2
related subgroups. As shown in Figure 4 (and validated
in Additional file 4, Figure S8), subtype 7 tumors have
significantly higher expression of basal related genes
(Supplemental methods) including AKT3, MET, EGFR,
CD44 and basal type cytokeratins (KRT5 and KRT17)
(Figure 4A, and Additional file 4, Figures S8, S9, S10).
In contrast, subgroup 10 tumors have higher expression
of the luminal-specific master regulator GATA3 (Figure
4B) [61,62]. Consistent with this observation, HCC202
cells (subgroup 10) had significantly higher mRNA levels
of GATA3 (Figure 4C) than AU565 cells (subgroup 7).
Although these results demonstrate that subgroup 10
tumors do not express the majority of basal-type mar-
kers and do exhibit certain luminal-type features, these
tumors did not have higher levels of luminal-type cyto-
keratins (KRT18 and KRT19) or several other luminal-
specific markers (Additional file 4, Figure S11).
The differential expression of a number of luminal
and basal-specific genes and pathways in subgroups 7
and 10 prompted us to further investigate this possibility
at the genome-wide level. We used the expression of a
well-annotated dataset of 24 luminal and 24 basal breast
cancer cell lines to develop a gene expression signature
with the ability to differentiate between basal and lumi-
nal tumor characteristics (Additional file 4, Figure
S12A). The basal-luminal signature was first validated
using a leave-one-out cross-validation among the cancer
cell lines (Additional file 4, Figure S12B). The accuracy
of the signature was then investigated by predicting the
basal or luminal characteristics of tumors and then
comparing the probability of basal or luminal status
against the intrinsic subtype based on previously
reported classifications of tumors [14] in both the pri-
mary and validation datasets. Our analysis determined
that most basal tumors were strongly predicted to be
basal-like (mean predicted probability: 0.933 and 0.992,
primary and validation datasets, respectively). The
majority of luminal tumors were predicted to have lumi-
nal-like characteristics (mean predicted probability:
0.321 and 0.438, respectively), albeit with a less uniform
distribution of predicted probabilities as compared to
basal tumors, likely owing to the high degree of hetero-
geneity in luminal breast tumors. However, the differ-
ence in the predicted probability between the intrinsic
subtypes was still highly significant for both the primary
and validation datasets (P < 0 . 0 0 0 1 )( F i g u r e4 D ,4 E ) .I n
contrast to basal and luminal tumors, ERBB2+ tumors
s h o w e daw i d e - r a n g eo fp r e d i cted basal-luminal charac-
teristics (Figure 4D, 4E). However, when we segregated
these tumors into the two pathway-based HER2 related
subgroups (subgroups 7 and 10), we found that subgroup
10 tumors were predicted to be predominantly luminal in
both the primary (congruence rate: 83%) and validation
(congruence rate: 60%) datasets, while most tumors in
subgroup 7 were predicted to be basal in the primary
(congruence rate: 72%) and validation (congruence rate:
81.1%) datasets when a predicted probability of 0.5 is
used as the cut-off for class assignment (Figure 4F, 4G)
and to determine the level of agreement between 7/10
subgroup identity and basal/luminal characteristics (con-
gruence rate).
To further examine the similarity between characteris-
tics of each of the two HER2 related subgroups and
basal/luminal cancer cell lines, we also performed the
reciprocal analysis. We developed a gene expression sig-
nature, using the samples from the primary dataset as
the training data, to differentiate between subgroup 7
and 10 tumor characteristics (Additional file 4, Figure
S13). Among the genes identified in this signature, we
noted, consistent with our earlier analyses, GATA3 and
MET enrichment in subgroup 10 and 7 tumors, respec-
tively, both of which are known to be preferentially
expressed in luminal and basal tumor, respectively
(Additional file 4, Figure S13). Although the intent of
this signature is not to assign samples to subgroups 7
and 10, but instead to investigate differences in group
characteristics, we first validated the ability of this signa-
ture to identify subgroup 7 and 10 characteristics using
samples in the validation dataset. As illustrated in Figure
4H, even with the inclusion of samples with a lower
probability (<0.70) of subgroup assignment, we demon-
strate that the majority of tumors assigned to subgroups
7 were predicted to have subgroup 7-like characteristics
(mean predicted probability: 0.7950) while samples
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activity were determined to have subgroup 10-like char-
acteristics (mean predicted probability: 0.2022) with an
overall congruence rate of 84.5% (P <0.0001). This sig-
nature and training model were then used to investigate
the subgroup 7 and subgroup 10 characteristics of the
breast cancer cell lines with established basal and lumi-
nal status. We found that the majority of the luminal
and basal cancer cells were characteristic of subgroups
10 and 7, respectively (congruence rate 81.3%, P
<0.0001), when a cutoff of 0.5 was used for class assign-
ment and to calculate congruence rate (Figure 4I).
Taken together, these data strongly suggested that sub-
group 10 and subgroup 7 tumors have molecular char-
acteristics that are consistent with luminal and basal
type breast cancers, respectively. These results, consis-
tent with several previous studies [3,11,63], suggest that
HER2 related tumor heterogeneity may arise as a conse-
q u e n c eo fb a s a la n dl u m i n a lc e l lf e a t u r e sa n dp r o v i d e
evidence supporting the hypothesis that the cell of ori-
gin for subgroup 7 tumors may have basal-like features,
whereas subgroup10 tumors may arise from progenitor
cells that have further differentiated and have features
more consistent with luminal-like tumors.
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Figure 4 HER2 related tumor subtypes are characterized by basal and luminal features.( A) Heatmap showing the expression level of
basal-type specific genes in subgroups 7 and 10 tumors. (B) Subgroup 10 tumors show significantly higher GATA3 mRNA expression (P = 0.0008)
as compared to subgroup 7 tumors. (C) Subgroup 10 cell lines (HCC202) demonstrate higher levels of GATA3 expression than subgroup7 cell
lines (AU565). (D) Validation of the luminal-basal signatures demonstrates an accurate prediction of basal (mean predicted probability: 0.933) and
luminal (mean predicted probability: 0.321) breast tumors (P <0.0001). (E) Validation of luminal-basal signature in validation dataset shown
accurate prediction of basal (mean predicted probability: 0.992) and luminal (mean predicted probability: 0.438) tumor status. (F) HER2 related
tumors from the primary dataset of 1,143 samples in subgroup 7 demonstrate basal-like features while subgroup 10 tumors are associated with
luminal-like features (P <0.0001). (G) HER2 related tumors in the validation dataset show significant enrichment of basal and luminal features in
subgroups 7 and 10, respectively (P <0.0001). (H) Validation of subgroup 7/10 signature to predict subgroup7 and 10 characteristics of tumors
assigned to subgroup 7 (mean predicted probability: 0.7950) and subgroup 10 (mean predicted probability: 0.2022) with a congruency rate of
84.5% (P <0.0001). (I) Classification of basal and luminal breast cancer cell lines demonstrates a congruency of 72% with basal and luminal status
(P <0.0001).
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correlations between hypoxia response, basal gene
expression, and HIF gene expression
Given that our results demonstrate a clear correlation
among basal-like features, hypoxia response and HIF
gene expression when comparing tumors in subgroups 7
and 10, we next investigated whether these observations
can be further extended to the heterogeneity among
HER2 related tumors irrespective of the classification
strategy. Since different classification strategies lead to
consistent but imperfect agreements sensitive to varying
thresholds, we sought to further determine the relation-
ship between the continuous variables of these proper-
ties. To investigate these correlations, we first compared
the average expression of basal associated genes
(detailed in Figure 4A) with the average expression of
hypoxia-related genes (detailed in Figure 3A). As
expected from our previous results, a significant, posi-
tive relationship was found to exist between average
hypoxia-and basal-related gene expression in tumors
assigned to subgroups 7 and 10 in both the primary
(Figure 5A, P <0.0001) and validation (Figure 5F, P
<0.0001) datasets. In order to investigate this relation-
ship among HER2 related tumors, we next examined
tumors classified as HER2 related (or ERBB2+) by the
intrinsic gene list [61,62] (Figure 5B, G) as well as in
those tumors that were reported to be HER2+ by IHC
(Figure 5C, H). As illustrated in Figures 5B (P <0.0001)
and 5C (P <0.0001) for the primary dataset, and vali-
dated in Figures 5G (P = 0.0012) and 5H (P = 0.0069),
this relationship is evident regardless of which of the
three independent methods is used to classify tumors as
HER2+ or HER2 related.
Furthermore, our data suggest that differential tumor
hypoxia response is associated in subgroups 7 and 10
tumors with expression of HIF mRNA (Figure 3).
Among the tumors classified as HER2+ by IHC, there is
a significant correlation between both HIF1A (HIF-1a)
(Figure 5D, P = 0.0256) and EPAS1 (HIF-2a) (Figure 5E,
P = 0.0038) expression and hypoxia-related gene expres-
sion. These results are further confirmed in the valida-
tion dataset as illustrated in Figures 5I (P = 0.0032) and
5J (P = 0.0094). Collectively, these data suggest that pat-
terns of basal-related gene expression, as well as HIF
levels, directly correlate with the expression of hypoxia-
related genes in HER2 related tumors regardless of
whether tumors are defined as HER2 related by a HER2
gene expression signature (subgroups 7/10), by the
intrinsic gene list (ERBB2+), or by HER2 IHC status.
Basal-like breast tumors exhibit an exaggerated hypoxia
response and increased HIF-1a expression but not lower
pO2
Our data suggest that tumors assigned to subgroup 7,
which express high levels of HIF-1a and hypoxia-related
genes, and subgroup 10, which express lower levels of
HIF-1a and hypoxia-related genes, have characteristics
in common with basal and luminal breast tumors,
respectively. Since our results demonstrate that the cor-
relation between average basal gene expression and
average hypoxia-related gene expression is consistent
across HER2 related tumors irrespective of classification
p<0.0001
p=0.0012
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p=0.0069
p=0.0256 p=0.0038
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AB
p<0.0001
p<0.0001
G
Figure 5 HER2 related tumors demonstrate a significant correlative relationship between basal-like and hypoxia-related gene
expression. A positive correlation between basal-like and hypoxia-related gene expression was observed in the tumors assigned to subgroups 7
(highlighted in red) and 10 (highlighted in blue) in the (A) primary (n = 112, P <0.0001) and (F) validation (n = 84, P <0.0001) datasets; in tumors
classified as ERBB2+ by the intrinsic gene list in the (B) primary (n = 115, P <0.0001) and (G) validation (n = 54, P = 0.0012) datasets; and in
tumors that are HER2+ by IHC in the (C) primary (n = 49, P <0.0001) and (H) validation (n = 33, P = 0.0069) datasets. HIF-1a mRNA expression in
IHC HER2+ tumors correlates with hypoxia-related gene expression in the (D) primary (n = 49, P = 0.0256) and (I) validation (n = 33, P = 0.0032)
datasets. EPAS1 (HIF-2a) mRNA expression in IHC HER2+ tumors correlates with hypoxia-related gene expression in the (E) primary (n = 49, P =
0.0038) and (J) validation (n = 33, P = 0.0094) datasets.
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ships were evident across all breast tumors given that
basal-like tumors have been previously reported to be
characterized by an enhanced hypoxia response [55,64].
As illustrated in Figure 6, a direct correlation was
observed in both the primary (Figure 6A, P <0.0001)
and validation (Figure 6D, P <0.0001) datasets between
basal-like and hypoxia-related gene expression. We
further examined the correlation between HIF-1a
expression and both hypoxia-related gene expression
(Figure 6B, E) and basal-like gene expression (Figure 6C,
F) across both the primary and validation dataset and
demonstrated a significant (P <0.0001) relationship
between both patterns of gene expression. These results,
consistent with previous studies [55,64] collectively sug-
gest that as tumors express more basal-like features,
irrespective of HER2 status, they also demonstrate
higher levels of hypoxia-related gene expression as well
as higher levels of HIF-1a. Consistent with the latter
point, we demonstrate that tumors assigned to sub-
groups 7 or that are classified as basal using the intrinsic
gene list express higher levels of HIF-1a as compared to
tumors assigned to subgroup 10 or classified as luminal,
respectively (Additional file 4, Figure S14, P <0.0001).
Given that significantly higher mRNA levels of HIF-1a
expression were noted in both HER2 related tumors and
basal tumors with high levels of predicted hypoxia
response, we next investigated whether the observed
levels of predicted hypoxia response correlated with
physical levels of oxygenation (pO2). We took advantage
of data from our previously published study that mea-
sured pO2 levels in situ in human breast cancer using
G
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Figure 6 Breast tumors with basal-like gene expression and basal epithelial cells differentially express hypoxia-related genes.A
significant positive correlation between basal-like and hypoxia-related gene expression was observed in breast tumors in the (A) primary (n =
1,143, P <0.0001) and (D) validation (n = 547, P <0.0001) datasets. A significant positive relationship was observed between HIF-1a gene
expression and hypoxia-related gene expression in the (B) primary (n = 1,143, P <0.0001) and (E) validation (n = 547, P <0.0001) datasets. A
significant positive relationship was observed between HIF-1a gene expression and basal-like gene expression in the (C) primary (n = 1,143, P
<0.0001) and (F) validation (n = 547, P <0.0001) datasets. (G) Normal basal epithelial cells express higher mRNA levels of HIF-1a (P <0.0001) and
EPAS1 (HIF-2a)( P<0.0001) as compared to normal breast luminal cells. (H) Normal basal epithelial cells demonstrate higher mRNA levels of three
hypoxia-induced genes (CA9, Glut1, and VEGFA) under normal and hypoxic conditions as compared to normal luminal epithelia.
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Page 11 of 17an Eppendorf electrode [33]. As shown in Figure S15,
basal tumors in this cohort also showed significantly
higher levels of hypoxia-induced gene expression (P =
0.0065) (Additional file 4, Figure. S15A) and HIF-1a
mRNA (P = 0.0261) (Additional file 4 Figure S15B)
when compared to luminal tumors. Importantly, no sig-
nificant difference (P = 0.28) was observed for pO2
levels (Additional file 4, Figure S15C). Therefore, these
data demonstrate that the exaggerated hypoxia response
observed in basal-like tumors cannot be solely attributed
to decreased oxygen levels. Instead, we postulated that
intrinsically higher mRNA expression of hypoxia regula-
tors, including HIF-1a, was responsible for the exagger-
ated hypoxia response in basal-type tumors.
Since basal-like breast tumors and HER2 related
tumors with basal-like characteristics, including sub-
group 7 tumors, demonstrated increased levels of HIF-
1a, we investigated whether such differences are a cell-
lineage phenomenon which can also delineate normal
basal and luminal mammary epithelial cells. Primary
breast epithelial cells were separated based on surface
expression of EPCAM (TACSTD1) from reduction
mammoplasty specimens and gene expression levels
were determined by microarray [47]. Both arrays and
real-time PCR showed that basal epithelial cells had a
greater than three-fold higher level of both HIF-1a and
HIF-2a expression compared to isogenic luminal epithe-
lial cells (Figure 6G). When placed under hypoxic condi-
tions, primary basal epithelial cells also demonstrated a
significantly greater hypoxia response (Figure 6H). From
these data, we hypothesize that the stronger hypoxia
response is associated with higher expression of hypoxia
regulators shared by both basal-like and HER2 related
tumors with basal-like characteristics, including sub-
group 7 tumors. Given that normal basal epithelial cells
also demonstrate enhanced HIF-1a expression, the asso-
ciation may be a cell-lineage distinction that can be
traced to systematic differences in the composition of
hypoxia regulators between normal, non-transformed
basal and luminal breast epithelial cells.
HIF-1a mRNA is responsible for the strong hypoxia
response in basal cells
Since our results demonstrated a correlation between
predicted hypoxia response and HIF-1a mRNA expres-
sion in both basal breast tumors and HER2 related
tumors with basal-like characteristics, including sub-
group 7 tumors, we next investigated whether HIF-1a
mRNA expression directly regulated the exaggerated
hypoxia-induced gene expression in these cells. We ana-
lyzed HIF1A (HIF-1a expression in six common breast
cancer cell lines to determine whether basal breast cell
lines, which have been previously reported to have a
higher hypoxia response [64], also express higher levels
of HIF1A (HIF-1a) and EPAS1 (HIF-2a) mRNA as com-
pared to luminal breast cancer cell lines. We determined
that the basal breast cancer cell lines (BT20, MDA-
MB231, MDA-MB157) had consistently higher mRNA
levels of both HIF1A (HIF-1a) (Figure 7A) and EPAS1
(HIF-2a) (Additional file 4, Figure S16A) when com-
pared to the luminal cell lines (MCF7, BT474, CAMA1).
Furthermore, we found that the basal breast cancer cell
lines also exhibited elevated expression levels of three
hypoxia-inducible genes (VEGF, GLUT1,a n dCA9)e v e n
under normoxia (Figure 7B and Additional file 4, Figure
S16B, C). These results are consistent with previous stu-
dies reporting a strong constitutive hypoxia response
and glycolytic phenotype in basal breast cancer cell lines
[64,65].
To investigate the roles of HIF1A (HIF-1a) and EPAS1
(HIF-2a) in the hypoxia response, we reduced expres-
sion of both genes by siRNA-mediated gene silencing in
MCF7 (luminal) and MDA-MB231 (basal) cells. This
gene silencing significantly reduced both transcripts in
MDA-MB231 cells to a level comparable to those in
MCF7 cells (Additional file 4, Figure S17A, B). Silencing
of HIF-1a, but not HIF-2a, mRNA significantly reduced
the exaggerated induction of VEGF (Figure 7C), GLUT1,
and CA9 expression (Additional file 4, Figure S17C, D)
in MDA-MB231 cells under hypoxia (1% pO2). Impor-
tantly, the silencing of HIF1A (HIF-1a),b u tn o tEPAS1
(HIF-2a), in MDA-MB231 reduced the induction of
these hypoxia-inducible genes to the levels comparable
to MCF7 cells (Figure 7C and Additional file 4, Figure
S17). Finally, we examined whether a similar mechanism
may be also important for the stronger hypoxia response
in the breast cancer cell lines in subgroup 7. Consistent
with our findings in the basal-breast cancer cell line,
AU565 cells (subgroup 7) demonstrated that silencing of
HIF1A (HIF-1a),b u tn o tEPAS1 (HIF-2a),l e dt ot h e
abolishment of the exaggerated hypoxia response seen
in these cells (Figure 7D and Additional file 4, Figure
S18). Taken together, these data are consistent with the
role of high levels of HIF-1a regulating the exaggerated
hypoxia response in both basal-like cancers and HER2
related tumors with basal-like characteristics and further
suggest that there is an apparent strong lineage-specific
component to this phenotype.
Discussion
Breast tumors are currently characterized in the clinic
based on tumor size, visual characteristics, and a limit
number of histochemical markers including estrogen
receptor, progesterone receptor, and HER2 receptor sta-
tus. Although these measures provide information about
tumor properties, they offer minimal insight into the
underlying biological mechanisms and provide only lim-
ited guidance in the development of therapeutic
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response of patients to treatment with the HER2 inhibi-
tor Herceptin; while HER2 negative patients do not
response to Herceptin, only fraction of HER2+ patients
respond to this treatment suggesting that additional
unrecognized heterogeneity must exist within these
patients and that more sophisticated strategies must be
employed to investigate tumor heterogeneity and to
develop therapeutic regimens.
Consistent with this hypothesis, a number of recent
studies have illustrated the heterogeneity of tumors dri-
ven by HER2 amplification. These studies have demon-
strated variability in patterns of copy number variation,
DNA methylation, and global gene expression [11,12].
Moreover, molecular subtypes based on the analysis of
gene expression patterns [13] as well as more complex
analyses of patterns of oncogenic and tumor suppressor
pathway activities [14] have identified classes that can
subdivide HER2 related tumors and provide further
insight into the molecular and clinical heterogeneity of
HER2 related tumors beyond the ERBB2+ molecular
classification. As previously discussed, we recently
reported a quantitative tumor classification scheme
based on patterns of pathway-associated signatures that
can better match the complexity of the tumor, and in
doing so, identified two subgroups characterized by high
levels of HER2 pathway activity [14]. In the current
study, we have utilized this framework to analyze non-
genetic factors in the context of genetic factors to define
the relationship between these two distinct sources of
tumor heterogeneity. We found a high degree of specific
co-regulation between non-genetic stresses and onco-
genic signaling pathways. Many of the co-regulated and
correlated pathways observed in the tumors are consis-
tent with previous findings to validate our approach. For
example, the strong co-regulation of hypoxia/EGFR/
C
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Figure 7 HIF-1a silencing inhibits the exaggerated hypoxia response in basal and subgroup 7 cancer cell lines.( A) Basal breast cancer
cell line demonstrate higher HIF-1a mRNA levels when compared to luminal breast cancer cell lines (B) Basal breast cancer cell line demonstrate
higher VEGF mRNA levels when compared to luminal breast cancer cell lines. (C, D) The silencing of HIF-1a but not EPAS1 (HIF-2a mRNA by
siRNA inhibits hypoxia-induced gene expression (VEGF) levels in basal breast cancer cell lines (C) and HER2-basal subtypes cell lines (D) under
both normal and hypoxic conditions as compared to their respective luminal-type breast cancer cell lines.
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between two groups of HER2 related tumors with signif-
icant differences in the pathway activities of these path-
ways. By analyzing patterns of non-genetic stress factors,
we demonstrate significant variation in patterns of pre-
dicted tumor microenvironment activity in two HER2
related subgroups classified by patterns of oncogenic
pathway activity. The HER2 related tumors that are
characterized by high levels of predicted hypoxia
response display enhanced levels of hypoxia-related
genes including HIF-1a, exhibit similar patterns of path-
way activity and gene expression as compared to basal-
like breast tumors. In contrast, the HER2 related tumors
that express low levels of hypoxia have oncogenic fea-
tures in common with luminal-like tumors. As illu-
strated in Figure 5, the correlation between hypoxia-
related gene expression, HIF gene expression, and basal-
like features is common across HER2 related tumors
irrespective of the classification strategy used to identify
these tumors; tumors classified by patterns of oncogenic
pathway activity (subgroups 7/10), by the intrinsic gene
list (ERBB2+) or by IHC (HER2+) all demonstrate this
characteristic. Moreover, we demonstrate that breast
tumors in general demonstrate this pattern of coinci-
dental gene expression where the increased expression
of basal-like genes correlates with the expression of HIF
and hypoxia-related genes. These results are supported
by, and are consistent with, several studies that suggest
that the observed heterogeneity in ER status among
HER2 related tumors is consistent with differences in the
basal and luminal origins of HER2-driven breast cancers
[3,11,63] as well as additional studies which report that
basal-like tumors have higher levels of the hypoxia gene
expression program compared to luminal breast tumors
[55,64]. Finally we demonstrate that HIF-1a expression
levels are higher in basal-like tumors, HER2 related
tumors with high hypoxia, and normal basal breast
epithelial cells and that HIF-1a regulates the expression
of hypoxia-induced genes. Our data support the idea that
the differences in the hypoxic response and mRNA level
of hypoxia regulators may be an intrinsic cell lineage
property associated with the origin of the tumor progeni-
tor cell. Consistent with this idea, it was recently sug-
gested that HER2 related tumors arise from late luminal
progenitor cells, an intermediate differentiation stage
between luminal progenitor cells from which basal-like
tumors arise and differentiated luminal cells from which
luminal A and B tumors arise [66]. Our results, in con-
junction with others [13] suggest that some HER2 related
tumors may arise from early luminal progenitor cells that
are more basal-like in nature whereas other HER2 related
tumors may arise from more differentiated, late luminal
progenitor cells resulting in tumors with more luminal-
like characteristics.
The positive correlation between both HIF-1a and
EPAS1 (HIF-2a) mRNA levels and overall breast tumor
hypoxia response suggests a role for transcriptional reg-
ulation of these hypoxia regulators. Our findings which
demonstrate that elevated expression of HIF-1a mRNA
in the basal and HER2 related breast tumors with basal-
like features, including subgroup 7 tumors, correlates
with hypoxia response are consistent with recent studies
reporting higher mRNA levels of HIF-1a and EPAS1
(HIF-2a) in glioma stem cells and renal epithelial cells
[24,25]. The consistent pattern of higher mRNA levels
of hypoxia-inducible factors in the less differentiated
glioma stem cells [25], hematopoietic stem cells [67,68]
and basal mammary epithelial cells (this study) suggests
that the differentiation status of these cells can be
coupled with the fine-tuning of the hypoxia response
and that these changes may be responsible for their dis-
tinct sensitivity to oxygen and metabolic requirements.
It has also been reported that pO2 and hypoxia-induci-
ble factors play important roles in the differentiation
processes of several different cell types [69,70] and has
been shown to induce de-differentiation of breast cancer
cells promoting invasion [71].
Our findings also have translation potential and
important therapeutic implications. Gaining a more
complete understanding of the biological mechanisms
regulating oncogenesis will enable the development of
more rational therapeutic strategies to enhance thera-
peutic efficacy. The cellular origin of HER2 related
tumors, the patterns of oncogenic pathway activity, and
the contributions of microenvironmental stresses may
be clinically relevant since differences in levels of PI3K,
EGFR, hypoxia, or MET activities in tumors have been
reported to contribute to various therapeutic responses
to HER2-targeting and other therapies, such as Trastu-
zumab (Herceptin). The influence of these factors on
response can be direct as in the case of PI3K [59,72], or
indirect, as in the case of development of drug resis-
tance under hypoxia [18]. Aberrant MET expression has
also been shown to confer resistance to the EGFR inhi-
bitor, Gefitinib [73]. Therefore, co-activation of these
pathways in subgroup 7 tumors provides further justifi-
cation for the development and investigation of thera-
peutic regimens that incorporate compounds targeting
more than one oncogenic pathway in order to increase
efficacy and reduce resistance.
Conclusions
We have incorporated non-genetic (microenvironmental
stresses) with genetic (oncogenic and tumor suppressor
genes) factors together in a pathway-based classification
framework to further dissect and identify biological
mechanisms underlying tumor heterogeneity. We vali-
date this approach by investigating the basis for the
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microenvironmental conditions of two HER2 related
tumor subgroups and found significant similarities with
many features distinguishing between the basal and
luminal intrinsic subtypes of breast cancers. By examin-
ing tumors identified as HER2 related by patterns of
oncogenic pathway activity (subgroups7/10), tumors
defined as HER2 related by the intrinsic gene list
(ERBB2+), or tumors that are HER2+ by IHC, we
demonstrate that these features are common to HER2
related tumors irrespective of the strategy used to char-
acterize them as HER2+. By revealing the role of HIF-
1a in regulating the hypoxia response and showing that
this mechanism, as well as the expression of additional
features, link HER2 related tumors in subgroup 7 with
basal-like breast tumors and subgroup 10 tumors with
luminal like breast tumors, respectively, we identify
additional oncogenic mechanisms and HER2 related
tumor heterogeneity that was not previously evident.
While our current studies focus only on a subset of che-
mical stresses, a similar approach is likely to be applic-
able for incorporating the mechanical factors, physical
forces, interstitial pressure, paracrine milieu and other
non-genetic conditions that may impact tumor pheno-
types. Such strategies are scalable to incorporate addi-
tional sources of information to investigate and discover
cross-talk between different pathways.
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